Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
CC transcript
Revance Therapeutics, Inc. (RVNC) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/08/2023 8-K Quarterly results
Docs: "Revance Reports Second Quarter 2023 Financial Results, Provides Corporate Update"
05/09/2023 8-K Quarterly results
Docs: "Revance Reports First Quarter 2023 Financial Results, Provides Corporate Update"
11/08/2022 8-K Quarterly results
08/09/2022 8-K Quarterly results
Docs: "Revance Reports Second Quarter 2022 Financial Results, Provides Corporate Update"
05/10/2022 8-K Quarterly results
02/28/2022 8-K Quarterly results
11/09/2021 8-K Quarterly results
Docs: "Revance Reports Third Quarter 2021 Financial Results, Provides Corporate Update"
08/05/2021 8-K Quarterly results
Docs: "Revance Reports Second Quarter 2021 Financial Results, Provides Corporate Update"
05/10/2021 8-K Quarterly results
02/22/2021 8-K Quarterly results
11/09/2020 8-K Quarterly results
Docs: "Revance Reports Third Quarter 2020 Financial Results and Provides Corporate Update",
"Revance Announces Results of Phase 2 Trial of DaxibotulinumtoxinA for Injection in Plantar Fasciitis"
08/06/2020 8-K Quarterly results
05/07/2020 8-K Quarterly results
02/24/2020 8-K Quarterly results
08/05/2019 8-K Quarterly results
05/08/2019 8-K Quarterly results
Docs: "Revance Reports First Quarter 2019 Financial Results and Provides Corporate Update - Conference call and webcast today at 4:30 p.m. ET -"
02/26/2019 8-K Quarterly results
11/01/2018 8-K Quarterly results
Docs: "Revance Releases Third Quarter 2018 Results - Chief Financial Officer Toby Schilke and Interim Head of Commercial- Aesthetics & Therapeutics Dustin Sjuts to assume roles on November 5 - NEWARK, Calif., November 1 - Revance Therapeutics, Inc. , a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions, today announced results for the third quarter ended September 30, 2018. Recent Company Highlights and Upcoming Milestones for DaxibotulinumtoxinA for Injection"
08/02/2018 8-K Quarterly results
Docs: "Revance Releases Second Quarter 2018 Results"
05/08/2018 8-K Quarterly results
Docs: "Revance Releases First Quarter 2018 Results"
11/02/2017 8-K Quarterly results
Docs: "Revance Releases Third Quarter 2017 Results -SAKURA 1 & 2 Phase 3 pivotal trials on track to report topline results before year-end 2017- - SAKURA 3 open-label safety study for glabellar lines has completed enrollment of more than 2,100 subjects -"
08/03/2017 8-K Quarterly results
Docs: "Revance Releases Second Quarter 2017 Results"
05/09/2017 8-K Form 8-K - Current report
02/27/2017 8-K Form 8-K - Current report
11/03/2016 8-K Form 8-K - Current report
05/09/2016 8-K Form 8-K - Current report
03/02/2016 8-K Quarterly results
Docs: "Revance Releases Fourth Quarter and Full Year 2015 Results - Announces 2016 Outlook - - On Track to Achieve Multiple Clinical Development Milestones in 2016 -"
11/09/2015 8-K Quarterly results
Docs: "Revance Therapeutics Releases Third Quarter 2015 Results - Momentum Continues on Multiple Clinical Trials for Both Drug Product Candidates -"
08/06/2015 8-K Quarterly results
Docs: "Revance Therapeutics Releases Second Quarter 2015 Results Plans to Move Forward on Multiple Clinical Trials for Both Drug Product Candidates"
05/13/2015 8-K Quarterly results
Docs: "Revance Therapeutics Releases First Quarter 2015 Financial Results Completes Enrollment in Two Key Clinical Trials: BELMONT Phase 2 Active Comparator Trial for Injectable RT002 and Open-Label Study for Topical RT001"
03/02/2015 8-K Quarterly results
Docs: "Revance Therapeutics Releases Fourth Quarter and Full Year 2014 Financial Results and Reiterates 2015 Outlook"
11/12/2014 8-K Quarterly results
Docs: "Revance Therapeutics Releases Third Quarter 2014 Results"
08/12/2014 8-K Quarterly results
Docs: "Revance Therapeutics Releases Second Quarter 2014 Financial Results - Reiterates Full-Year Financial Guidance -"
05/13/2014 8-K Quarterly results
Docs: "Revance Therapeutics Releases First Quarter 2014 Financial Results - Reiterates Full-Year Financial Guidance -"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy